Top

Published in:

Open Access 01-12-2012 | Research

Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer's disease

Authors: Shih-Yuan Chen, Ta-Fu Chen, Liang-Chuan Lai, Jen-Hau Chen, Yu Sun, Li-Li Wen, Ping-Keung Yip, Yi-Min Chu, Yen-Ching Chen

Published in: Journal of Neuroinflammation | Issue 1/2012

Abstract

Background

Interleukin 6 (IL-6) has been related to beta-amyloid aggregation and the appearance of hyperphosphorylated tau in Alzheimer's disease (AD) brain. However, previous studies relating IL-6 genetic polymorphisms to AD included few and unrepresentative single nucleotide polymorphisms (SNPs) and the results were inconsistent.

Methods

This is a case-control study. A total of 266 patients with AD, aged≧65, were recruited from three hospitals in Taiwan (2007-2010). Controls (n = 444) were recruited from routine health checkups and volunteers of the hospital during the same period of time. Three common IL-6 haplotype-tagging SNPs were selected to assess the association between IL-6 polymorphisms and the risk of late-onset AD (LOAD).

Results

Variant carriers of IL-6 rs1800796 and rs1524107 were significantly associated with a reduced risk of LOAD [(GG + GC vs. CC): adjusted odds ratio (AOR) = 0.64 and (CC + CT vs. TT): AOR = 0.60, respectively]. Haplotype CAT was associated with a decreased risk of LOAD (0 and 1 copy vs. 2 copies: AOR = 0.65, 95% CI = 0.44-0.95). These associations remained significant in ApoE e4 non-carriers only. Hypertension significantly modified the association between rs2069837 polymorphisms and the risk of LOAD (p _interaction = 0.03).

Conclusions

IL-6 polymorphisms are associated with reduced risk of LOAD, especially in ApoE e4 non-carriers. This study identified genetic markers for predicting LOAD in ApoE e4 non-carriers.

Alzheimer's Association: 2010 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia. [http://www.alz.org/alzheimers_disease_facts_figures.asp?type=homepage]

Fuh JL, Wang SJ: Dementia in Taiwan: past, present, and future. Acta Neurol Taiwan 2008, 17:153–161.PubMed

Gadient RA, Otten UH: Interleukin-6 (IL-6)--a molecule with both beneficial and destructive potentials. Prog Neurobiol 1997, 52:379–390.CrossRefPubMed

Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH: Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci USA 1997, 94:1500–1505.CrossRefPubMedPubMedCentral

Castell JV, Andus T, Kunz D, Heinrich PC: Interleukin-6: the major regulator of acute-phase protein synthesis in man and rat. Ann NY Acad Sci 1989, 557:87–99.CrossRefPubMed

Quintanilla RA, Orellana DI, Gonzalez-Billáult C, Maccioni RB: Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 2004, 295:245–257.CrossRefPubMed

Querfurth HW, LaFerla FM: Alzheimer's disease. N Engl J Med 2010, 362:329–344.CrossRefPubMed

Licastro F, Grimaldi LM, Bonafè M, Martina C, Olivieri F, Cavallone L, Giovanietti S, Masliah E, Franceschi C: Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 2003, 24:921–926.CrossRefPubMed

Arosio B, Trabattoni D, Galimberti L, Bucciarelli P, Fasano F, Calabresi C, Cazzullo CL, Vergani C, Annoni G, Clerici M: Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol Aging 2004, 25:1009–1015.CrossRef

10.

Depboylu C, Lohmüller F, Gocke P, Du Y, Zimmer R, Gasser T, Klockgether T, Dodel RC: An interleukin-6 promoter variant is not associated with an increased risk for Alzheimer's disease. Dement Geriatr Cogn Disord 2004, 17:170–173.CrossRefPubMed

11.

van Oijen M, Arp PP, de Jong FJ, Hofman A, Koudstaal PJ, Uitterlinden AG, Breteler MM: Polymorphisms in the interleukin 6 and transforming growth factor beta1 gene and risk of dementia. The Rotterdam study. Neurosci Lett 2006, 402:113–117.CrossRefPubMed

12.

He MX, Yang WL, Zhang MM, Lian YJ, Hua HY, Zeng JS, Zhang LR: Association between interleukin-6 gene promoter--572 C/G polymorphism and the risk of sporadic Alzheimer's disease. Neurol Sci 2010, 31:165–168.CrossRefPubMed

13.

Wang M, Jia J: The interleukin-6 gene--572 C/G promoter polymorphism modifies Alzheimer's risk in ApoE epsilon 4 carriers. Neurosci Lett 2010, 482:260–263.CrossRefPubMed

14.

Nishimura M, Sakamoto T, Kaji R, Kawakami H: Influence of polymorphisms in the genes for cytokines and glutathione S-transferase omega on sporadic Alzheimer's disease. Neurosci Lett 2004, 368:140–143.CrossRefPubMed

15.

Lim CS, Zheng S, Kim YS, Ahn C, Han JS, Kim S, Lee JS, Chae DW: The -174 G to C polymorphism of interleukin-6 gene is very rare in Koreans. Cytokine 2002, 19:52–54.CrossRefPubMed

16.

Fillit H, Nash DT, Rundek T, Zuckerman A: Cardiovascular risk factors and dementia. Am J Geriatr Pharmacother 2008, 6:100–118.CrossRefPubMed

17.

Román GC: Vascular dementia prevention: a risk factor analysis. Cerebrovasc Dis 2005,20(Suppl 2):91–100.CrossRefPubMed

18.

Stozická Z, Zilka N, Novák M: Risk and protective factors for sporadic Alzheimer's disease. Acta Virol 2007, 51:205–222.PubMed

19.

American Psychiatric Association: Diagnostic and statistical manual of mental disorders. Washington, DC. 4th edition. 1994.

20.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939–944.CrossRefPubMed

21.

Pfeiffer E: A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975, 23:433–441.CrossRefPubMed

22.

Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ: Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005, 65:11771–11778.CrossRefPubMed

23.

Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D: The structure of haplotype blocks in the human genome. Science 2002, 296:2225–2229.CrossRefPubMed

24.

Stram DO, Leigh Pearce C, Bretsky P, Freedman M, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Thomas DC: Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003, 55:179–190.CrossRefPubMed

25.

Chapman J, Estupiñan J, Asherov A, Goldfarb LG: A simple and efficient method for apolipoprotein E genotype determination. Neurology 1996, 46:1484–1485.CrossRefPubMed

26.

Ghebranious N, Ivacic L, Mallum J, Dokken C: Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology. Nucleic Acids Res 2005,33(17):e149.CrossRefPubMedPubMedCentral

27.

Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995, 57:289–300.

28.

Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, Humphries SE: Interleukin-6 gene -174 g > c and--572 g > c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001, 21:1458–1463.CrossRefPubMed

29.

Wong LY, Leung RY, Ong KL, Cheung BM: Plasma levels of fibrinogen and C-reactive protein are related to interleukin-6 gene -572 C > G polymorphism in subjects with and without hypertension. J Hum Hypertens 2007, 21:875–882.CrossRefPubMed

30.

Nonogaki K, Iguchi A: Stress, acute hyperglycemia, and hyperlipidemia role of the autonomic nervous system and cytokines. Trends Endocrinol Metab 1997, 8:192–197.CrossRefPubMed

31.

Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, Miao F, Ross CJ, van Eck M, Hayden MR, van Nostrand W, St George-Hyslop P, Westaway D, Wellington CL: Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis 2006, 24:114–127.CrossRefPubMed

32.

Hajjar IM, Keown M, Lewis P, Almor A: Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study. Am J Alzheimers Dis Other Demen 2008, 23:77–83.CrossRefPubMed

33.

Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B: Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010, 12:b5465.CrossRef

34.

Zheng SL, Liu W, Wiklund F, Dimitrov L, Bälter K, Sun J, Adami HO, Johansson JE, Sun J, Chang B, Loza M, Turner AR, Bleecker ER, Meyers DA, Carpten JD, Duggan D, Isaacs WB, Xu J, Grönberg H: A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate 2006,66(14):1556–1564.CrossRefPubMed

35.

El Fakiri F, Bruijnzeels MA, Hoes AW: No evidence for marked ethnic differences in accuracy of self-reported diabetes, hypertension, and hypercholesterolemia. J Clin Epidemiol 2007, 60:1271–1279.CrossRefPubMed

36.

Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodehceffer RJ: Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004, 57:1096–1103.CrossRefPubMed

37.

St Sauver JL, Hagen PT, Cha SS, Bagniewski SM, Mandrekar JN, Curoe AM, Rodeheffer RJ, Roger VL, Jacobsen SJ: Agreement between patient reports of cardiovascular disease and patient medical records. Mayo Clin Proc 2005, 80:203–210.CrossRefPubMed

Title: Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer's disease
Authors: Shih-Yuan Chen
Ta-Fu Chen
Liang-Chuan Lai
Jen-Hau Chen
Yu Sun
Li-Li Wen
Ping-Keung Yip
Yi-Min Chu
Yen-Ching Chen
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Neuroinflammation / Issue 1/2012
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/1742-2094-9-21

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer's disease

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Small interfering RNA-mediated suppression of Ccl2 in Müller cells attenuates microglial recruitment and photoreceptor death following retinal degeneration

Delayed mGluR5 activation limits neuroinflammation and neurodegeneration after traumatic brain injury

Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies

A single intraperitoneal injection of endotoxin in rats induces long-lasting modifications in behavior and brain protein levels of TNF-α and IL-18

Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury

Rescue from acute neuroinflammation by pharmacological chemokine-mediated deviation of leukocytes